Trials / Completed
CompletedNCT02662647
Decitabine Based Chemotherapy Followed by Haploidentical Lymphocyte Infusion for Elderly Patients With AML
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Chinese PLA General Hospital · Academic / Other
- Sex
- All
- Age
- 60 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Demethylating agent decitabine enhances the immunogenicity of leukemia cells by inducing the expression of cancer testis antigens (CTAs),MHC class I and II molecules,costimulatory molecules and adhesion molecules. The leukemias cells treated by decitabine will become more sensitive to the following adoptive T cell therapy.We proposed a hypothesis that decitabine-based chemotherapy acts in synergestic with haploidentical lymphocyte infusion in eliciting leukemia specific cytotoxic lymphocyte(CTL) and diminishing leukemic cells.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Decitabine 20 mg/m²/day for 5 days |
Timeline
- Start date
- 2015-04-01
- Primary completion
- 2018-06-01
- Completion
- 2019-03-01
- First posted
- 2016-01-25
- Last updated
- 2019-06-10
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02662647. Inclusion in this directory is not an endorsement.